HU224814B1 - Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases - Google Patents

Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases Download PDF

Info

Publication number: HU224814B1
Authority: HU; Hungary
Prior art keywords: disease; compound; disorder; administered; propane
Prior art date: 1995-12-28

Application number

HU9800034A

Other languages

English (en)

Hungarian (hu)

Inventor

Tsuneo Fujii

Tomonori Imayoshi

Tadashi Mishina

Koji Teshima

Original Assignee

Mitsubishi Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-28

Filing date

1996-12-24

Publication date

2006-02-28

1996-12-24 Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp

1999-05-28 Publication of HUP9800034A2 publication Critical patent/HUP9800034A2/hu

1999-12-28 Publication of HUP9800034A3 publication Critical patent/HUP9800034A3/hu

2006-02-28 Publication of HU224814B1 publication Critical patent/HU224814B1/hu

Links

230000000699 topical effect Effects 0.000 title claims description 7
239000003814 drug Substances 0.000 title claims description 4
208000026278 immune system disease Diseases 0.000 title claims 3
208000027866 inflammatory disease Diseases 0.000 title claims 2
238000002360 preparation method Methods 0.000 title description 9
230000002757 inflammatory effect Effects 0.000 title description 4
YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical class OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 title 1
239000000203 mixture Substances 0.000 claims description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
238000011282 treatment Methods 0.000 claims description 21
201000010099 disease Diseases 0.000 claims description 18
239000002253 acid Substances 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 13
239000000243 solution Substances 0.000 claims description 11
239000000443 aerosol Substances 0.000 claims description 9
208000023275 Autoimmune disease Diseases 0.000 claims description 8
210000000056 organ Anatomy 0.000 claims description 8
206010061218 Inflammation Diseases 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 7
230000004054 inflammatory process Effects 0.000 claims description 7
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 6
108010036949 Cyclosporine Proteins 0.000 claims description 6
229960001265 ciclosporin Drugs 0.000 claims description 6
239000003889 eye drop Substances 0.000 claims description 6
239000003018 immunosuppressive agent Substances 0.000 claims description 6
201000004624 Dermatitis Diseases 0.000 claims description 5
229930182912 cyclosporin Natural products 0.000 claims description 5
KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 5
229960003444 immunosuppressant agent Drugs 0.000 claims description 5
230000001861 immunosuppressant effect Effects 0.000 claims description 5
208000017169 kidney disease Diseases 0.000 claims description 4
208000023504 respiratory system disease Diseases 0.000 claims description 4
229930105110 Cyclosporin A Natural products 0.000 claims description 3
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 3
229940014456 mycophenolate Drugs 0.000 claims description 3
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 3
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
230000002441 reversible effect Effects 0.000 claims description 3
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
229960002930 sirolimus Drugs 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
NWJQLQGQZSIBAF-MSLXHMNKSA-N (1R,9S,12S,13R,14S,17R,18Z,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone hydrate Chemical compound O.C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 NWJQLQGQZSIBAF-MSLXHMNKSA-N 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims description 2
229960002170 azathioprine Drugs 0.000 claims description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
210000004204 blood vessel Anatomy 0.000 claims description 2
230000003463 hyperproliferative effect Effects 0.000 claims description 2
208000028867 ischemia Diseases 0.000 claims description 2
229950000844 mizoribine Drugs 0.000 claims description 2
210000004400 mucous membrane Anatomy 0.000 claims description 2
230000000414 obstructive effect Effects 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
230000002685 pulmonary effect Effects 0.000 claims description 2
208000017520 skin disease Diseases 0.000 claims description 2
229940083542 sodium Drugs 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
229960001569 tacrolimus monohydrate Drugs 0.000 claims description 2
210000001519 tissue Anatomy 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims 2
208000010201 Exanthema Diseases 0.000 claims 1
206010020751 Hypersensitivity Diseases 0.000 claims 1
206010067125 Liver injury Diseases 0.000 claims 1
230000007815 allergy Effects 0.000 claims 1
201000005884 exanthem Diseases 0.000 claims 1
229960002706 gusperimus Drugs 0.000 claims 1
231100000234 hepatic damage Toxicity 0.000 claims 1
230000008818 liver damage Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 claims 1
244000052769 pathogen Species 0.000 claims 1
206010037844 rash Diseases 0.000 claims 1
230000001960 triggered effect Effects 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 81
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 22
-1 pyranylphenyl lactones Chemical class 0.000 description 19
239000003599 detergent Substances 0.000 description 17
239000002674 ointment Substances 0.000 description 16
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 14
239000003995 emulsifying agent Substances 0.000 description 14
239000004480 active ingredient Substances 0.000 description 13
235000002639 sodium chloride Nutrition 0.000 description 13
239000008194 pharmaceutical composition Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
239000012049 topical pharmaceutical composition Substances 0.000 description 11
238000010521 absorption reaction Methods 0.000 description 10
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
239000007788 liquid Substances 0.000 description 9
239000000829 suppository Substances 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
239000006071 cream Substances 0.000 description 8
125000001931 aliphatic group Chemical group 0.000 description 7
239000012153 distilled water Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
230000003381 solubilizing effect Effects 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000654 additive Substances 0.000 description 6
208000006673 asthma Diseases 0.000 description 6
208000010668 atopic eczema Diseases 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
150000003626 triacylglycerols Chemical class 0.000 description 6
208000026935 allergic disease Diseases 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000004359 castor oil Substances 0.000 description 5
235000019438 castor oil Nutrition 0.000 description 5
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
239000003921 oil Substances 0.000 description 5
239000003883 ointment base Substances 0.000 description 5
230000002265 prevention Effects 0.000 description 5
239000003760 tallow Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000004166 Lanolin Substances 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000000172 allergic effect Effects 0.000 description 4
230000001363 autoimmune Effects 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 4
239000000796 flavoring agent Substances 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
235000019388 lanolin Nutrition 0.000 description 4
229940039717 lanolin Drugs 0.000 description 4
238000000034 method Methods 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
239000012188 paraffin wax Substances 0.000 description 4
235000019271 petrolatum Nutrition 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 4
239000007921 spray Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000001993 wax Substances 0.000 description 4
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
201000004384 Alopecia Diseases 0.000 description 3
206010010741 Conjunctivitis Diseases 0.000 description 3
206010012438 Dermatitis atopic Diseases 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
206010029164 Nephrotic syndrome Diseases 0.000 description 3
239000005642 Oleic acid Substances 0.000 description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 3
201000008937 atopic dermatitis Diseases 0.000 description 3
229960001950 benzethonium chloride Drugs 0.000 description 3
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 3
238000010322 bone marrow transplantation Methods 0.000 description 3
239000003086 colorant Substances 0.000 description 3
239000000645 desinfectant Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
229940012356 eye drops Drugs 0.000 description 3
238000009472 formulation Methods 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000006210 lotion Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229940100662 nasal drops Drugs 0.000 description 3
235000021313 oleic acid Nutrition 0.000 description 3
239000003002 pH adjusting agent Substances 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
239000003380 propellant Substances 0.000 description 3
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000002511 suppository base Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical class OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
208000026872 Addison Disease Diseases 0.000 description 2
208000032467 Aplastic anaemia Diseases 0.000 description 2
208000009137 Behcet syndrome Diseases 0.000 description 2
208000020084 Bone disease Diseases 0.000 description 2
QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000723346 Cinnamomum camphora Species 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
VIZORQUEIQEFRT-UHFFFAOYSA-N Diethyl adipate Chemical compound CCOC(=O)CCCCC(=O)OCC VIZORQUEIQEFRT-UHFFFAOYSA-N 0.000 description 2
UDSFAEKRVUSQDD-UHFFFAOYSA-N Dimethyl adipate Chemical compound COC(=O)CCCCC(=O)OC UDSFAEKRVUSQDD-UHFFFAOYSA-N 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
206010014954 Eosinophilic fasciitis Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
208000009329 Graft vs Host Disease Diseases 0.000 description 2
208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 2
GLZPCOQZEFWAFX-UHFFFAOYSA-N KU0063794 Natural products CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
206010037575 Pustular psoriasis Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
125000005907 alkyl ester group Chemical group 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000015278 beef Nutrition 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
229910021538 borax Inorganic materials 0.000 description 2
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
239000004327 boric acid Substances 0.000 description 2
210000000621 bronchi Anatomy 0.000 description 2
229930008380 camphor Natural products 0.000 description 2
229960000846 camphor Drugs 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000004203 carnauba wax Substances 0.000 description 2
235000013869 carnauba wax Nutrition 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
201000001981 dermatomyositis Diseases 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
229940031578 diisopropyl adipate Drugs 0.000 description 2
UHGPEWTZABDZCE-UHFFFAOYSA-N dipropyl decanedioate Chemical compound CCCOC(=O)CCCCCCCCC(=O)OCCC UHGPEWTZABDZCE-UHFFFAOYSA-N 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
239000006196 drop Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
239000003925 fat Substances 0.000 description 2
SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical compound Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
208000024908 graft versus host disease Diseases 0.000 description 2
210000004209 hair Anatomy 0.000 description 2
230000003676 hair loss Effects 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
201000006334 interstitial nephritis Diseases 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
206010023332 keratitis Diseases 0.000 description 2
201000010260 leiomyoma Diseases 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
229960003511 macrogol Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
244000000010 microbial pathogen Species 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
239000007923 nasal drop Substances 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
229940046781 other immunosuppressants in atc Drugs 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
235000015277 pork Nutrition 0.000 description 2
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000004328 sodium tetraborate Substances 0.000 description 2
235000010339 sodium tetraborate Nutrition 0.000 description 2
229960002920 sorbitol Drugs 0.000 description 2
238000005507 spraying Methods 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
125000005274 4-hydroxybenzoic acid group Chemical class 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
201000010000 Agranulocytosis Diseases 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
206010002921 Aortitis Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
206010008609 Cholangitis sclerosing Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010066968 Corneal leukoma Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
240000004244 Cucurbita moschata Species 0.000 description 1
235000009854 Cucurbita moschata Nutrition 0.000 description 1
235000009852 Cucurbita pepo Nutrition 0.000 description 1
201000003066 Diffuse Scleroderma Diseases 0.000 description 1
208000021866 Dressler syndrome Diseases 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
208000004332 Evans syndrome Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
239000005792 Geraniol Substances 0.000 description 1
GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
208000000038 Hypoparathyroidism Diseases 0.000 description 1
206010021074 Hypoplastic anaemia Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
201000002287 Keratoconus Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
208000027530 Meniere disease Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
208000024599 Mooren ulcer Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000027771 Obstructive airways disease Diseases 0.000 description 1
206010031264 Osteonecrosis Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010048908 Seasonal allergy Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
239000004288 Sodium dehydroacetate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010047112 Vasculitides Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
201000006966 adult T-cell leukemia Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000001414 amino alcohols Chemical class 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
235000019568 aromas Nutrition 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
208000006424 autoimmune oophoritis Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
150000003976 azacycloalkanes Chemical class 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
229940116229 borneol Drugs 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000007765 cera alba Substances 0.000 description 1
239000007766 cera flava Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
208000029771 childhood onset asthma Diseases 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
208000023819 chronic asthma Diseases 0.000 description 1
201000010002 cicatricial pemphigoid Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
239000008294 cold cream Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
239000002826 coolant Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
AYBSICMEDZIQTK-UHFFFAOYSA-K dipotassium sodium phosphoric acid phosphate Chemical compound [Na+].[K+].[K+].OP(O)(O)=O.[O-]P([O-])([O-])=O AYBSICMEDZIQTK-UHFFFAOYSA-K 0.000 description 1
PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
HXOLFXRMWWHLMH-UHFFFAOYSA-L disodium boric acid carbonate Chemical compound [Na+].[Na+].OB(O)O.[O-]C([O-])=O HXOLFXRMWWHLMH-UHFFFAOYSA-L 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
229940124274 edetate disodium Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000008344 egg yolk phospholipid Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
208000010227 enterocolitis Diseases 0.000 description 1
201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
239000010642 eucalyptus oil Substances 0.000 description 1
229940044949 eucalyptus oil Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940113087 geraniol Drugs 0.000 description 1
125000005456 glyceride group Polymers 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
231100000753 hepatic injury Toxicity 0.000 description 1
206010019692 hepatic necrosis Diseases 0.000 description 1
230000007866 hepatic necrosis Effects 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000008311 hydrophilic ointment Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003903 intestinal lesions Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
208000024884 ischemic bone disease Diseases 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
239000003350 kerosene Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
229940040145 liniment Drugs 0.000 description 1
239000000865 liniment Substances 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
239000003949 liquefied natural gas Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
235000012254 magnesium hydroxide Nutrition 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
208000008585 mastocytosis Diseases 0.000 description 1
239000000155 melt Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
239000004200 microcrystalline wax Substances 0.000 description 1
235000019808 microcrystalline wax Nutrition 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229940074096 monoolein Drugs 0.000 description 1
235000013923 monosodium glutamate Nutrition 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
208000009928 nephrosis Diseases 0.000 description 1
231100001027 nephrosis Toxicity 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
150000002888 oleic acid derivatives Polymers 0.000 description 1
150000002889 oleic acids Polymers 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
201000005737 orchitis Diseases 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003973 paint Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
235000019809 paraffin wax Nutrition 0.000 description 1
208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
208000008423 pleurisy Diseases 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
230000003658 preventing hair loss Effects 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000008213 purified water Substances 0.000 description 1
201000010914 pustulosis of palm and sole Diseases 0.000 description 1
208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012827 research and development Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
206010048628 rheumatoid vasculitis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
208000010157 sclerosing cholangitis Diseases 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019259 sodium dehydroacetate Nutrition 0.000 description 1
229940079839 sodium dehydroacetate Drugs 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229940073490 sodium glutamate Drugs 0.000 description 1
235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001433 sodium tartrate Substances 0.000 description 1
229960002167 sodium tartrate Drugs 0.000 description 1
235000011004 sodium tartrates Nutrition 0.000 description 1
DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
CLJTZNIHUYFUMR-UHFFFAOYSA-M sodium;hydrogen carbonate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CLJTZNIHUYFUMR-UHFFFAOYSA-M 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
229960005078 sorbitan sesquioleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
235000020354 squash Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
LEAHFJQFYSDGGP-UHFFFAOYSA-K trisodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].OP(O)([O-])=O.OP([O-])([O-])=O LEAHFJQFYSDGGP-UHFFFAOYSA-K 0.000 description 1
239000010681 turmeric oil Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000010497 wheat germ oil Substances 0.000 description 1
210000002268 wool Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

HU9800034A 1995-12-28 1996-12-24 Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases HU224814B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP34250395		1995-12-28
PCT/JP1996/003757 WO1997024112A1 (en)	1995-12-28	1996-12-24	External preparation

Publications (3)

Publication Number	Publication Date
HUP9800034A2 HUP9800034A2 (hu)	1999-05-28
HUP9800034A3 HUP9800034A3 (en)	1999-12-28
HU224814B1 true HU224814B1 (en)	2006-02-28

Family

ID=18354257

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU9800034A HU224814B1 (en)	1995-12-28	1996-12-24	Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases

Country Status (16)

Country	Link
US (2)	US6121329A (de)
EP (1)	EP0812588B1 (de)
AT (1)	ATE279185T1 (de)
AU (1)	AU705320B2 (de)
CA (1)	CA2213989C (de)
CZ (1)	CZ285953B6 (de)
DE (1)	DE69633613T2 (de)
ES (1)	ES2230571T3 (de)
HU (1)	HU224814B1 (de)
IL (1)	IL121625A (de)
NZ (1)	NZ324453A (de)
PT (1)	PT812588E (de)
RU (1)	RU2156127C2 (de)
SI (1)	SI0812588T1 (de)
SK (1)	SK282225B6 (de)
WO (1)	WO1997024112A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002241272A (ja) *	1996-07-18	2002-08-28	Mitsubishi Pharma Corp	医薬処方組成物
US6476004B1 (en)	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
JPH11209277A (ja) *	1998-01-19	1999-08-03	Yoshitomi Pharmaceut Ind Ltd	医薬組成物
GB9624038D0 (en)	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
KR20000075745A (ko)	1997-02-27	2000-12-26	가마후라 아키오	의약 조성물
CA2326222C (en)	1998-04-27	2008-09-23	Fujisawa Pharmaceutical Co., Ltd.	Medicinal compositions
US20020006901A1 (en) *	1999-02-05	2002-01-17	Aldo T. Iacono	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US6541462B1 (en) *	1999-03-25	2003-04-01	Center For Molecular Medicine And Immunology	Sphingomyelin enhancement of tumor therapy
US7683044B2 (en) *	1999-03-25	2010-03-23	Center For Molecular Medicine And Immunology	Sphingomyelin therapy of autoimmune disease
EP1315735A4 (de)	2000-08-31	2005-04-06	Merck & Co Inc	Phosphat-derivate als immunoregulatorische verbindungen
JP4318921B2 (ja) *	2001-02-22	2009-08-26	ノバルティスアクチエンゲゼルシャフト	移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用
US20030124174A1 (en) *	2001-10-25	2003-07-03	Endo Pharmaceuticals, Inc	Method for treating non-neuropathic pain
DK1471054T3 (da) *	2002-01-11	2009-11-09	Daiichi Sankyo Co Ltd	Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
AU2003233119A1 (en)	2002-05-08	2003-11-11	Neuronova Ab	Modulation of neural stem cells with s1p or lpa receptor agonists
RU2220738C1 (ru) *	2002-08-30	2004-01-10	Гапонюк Петр Яковлевич	Средство для лечения ринита
KR20050092429A (ko) *	2003-01-22	2005-09-21	니찌방 가부시기가이샤	안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
GB0307866D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
PE20130200A1 (es)	2003-04-08	2013-03-09	Novartis Ag	Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
RU2233163C1 (ru) *	2003-04-30	2004-07-27	Государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт"	Способ лечения акантолитической пузырчатки
EP1484057A1 (de) *	2003-06-06	2004-12-08	Aventis Pharma Deutschland GmbH	Verwendung von 2-amino-1,3-propandiolderivaten zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen
US7524887B2 (en)	2003-06-06	2009-04-28	Sanofi-Aventis Deutschland Gmbh	2-amino-1,3-propanediol compounds for the treatment of acute pain
BRPI0414193A (pt) *	2003-09-09	2006-10-31	3M Innovative Properties Co	composição antimicrobiana, kit antimicrobiano e métodos de usar a composição e de aplicar uma composição antimicrobiana a um substrato
US20050058673A1 (en)	2003-09-09	2005-03-17	3M Innovative Properties Company	Antimicrobial compositions and methods
GB0324210D0 (en)	2003-10-15	2003-11-19	Novartis Ag	Organic compounds
GB0329498D0 (en) *	2003-12-19	2004-01-28	Novartis Ag	Organic compounds
GB0500020D0 (en) *	2005-01-04	2005-02-09	Novartis Ag	Organic compounds
NZ549162A (en)	2004-02-24	2009-12-24	Sankyo Co	Amino-pyrrol alcohol compounds
US20050232894A1 (en) *	2004-04-20	2005-10-20	Weiner Gregory M	Antimicrobial skin treatment composition and methods for producing and using an antimicrobial skin treatment composition
PL1773307T3 (pl) *	2004-07-30	2015-03-31	Novartis Ag	Preparaty 2-amino-1,3-propanodioli i ich analogów
MX2007003789A (es) *	2004-10-04	2007-07-20	Qlt Usa Inc	Suministro ocular de formulaciones polimericas para suministro.
US8313763B2 (en) *	2004-10-04	2012-11-20	Tolmar Therapeutics, Inc.	Sustained delivery formulations of rapamycin compounds
KR20070085465A (ko) *	2004-11-29	2007-08-27	노파르티스 아게	Ｓ１ｐ 수용체 효능제의 투여 용법
US20080233053A1 (en) *	2005-02-07	2008-09-25	Pharmalight Inc.	Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
GB0504544D0 (en) *	2005-03-04	2005-04-13	Novartis Ag	Organic compounds
BRPI0608690B8 (pt)	2005-03-10	2021-05-25	3M Innovative Properties Co	uso de uma composição antimicrobiana
WO2006099325A2 (en)	2005-03-10	2006-09-21	3M Innovative Properties Company	Methods of treating ear infections
US20060229364A1 (en) *	2005-03-10	2006-10-12	3M Innovative Properties Company	Antiviral compositions and methods of use
BRPI0608691A2 (pt)	2005-03-10	2010-12-07	3M Innovative Properties Company	composição antimicrobiana, e, métodos para matar ou inativar microorganismos em tecido da mucosa de um mamìfero, para tratar uma lesão ou ferimento infectado, para descolonização de microorganismos, para proporcionar eficácia antimicrobiana residual sobre uma superfìcie e para tratar uma condição
US8633161B2 (en) *	2005-03-24	2014-01-21	The Ohio State University Research Foundation	Therapeutic agents for the treatment of leukemia
PT1905453E (pt) *	2005-07-13	2012-12-04	Santen Pharmaceutical Co Ltd	Composição conservante para utilização oftálmica
WO2007098139A2 (en) *	2006-02-21	2007-08-30	The Ohio State University Research Foundation	Anticancer agents
WO2007143081A2 (en) *	2006-06-02	2007-12-13	The Ohio State University Research Foundation	Therapeutic agents for the treatment of lymphoid malignancies
US20080075793A1 (en) *	2006-09-21	2008-03-27	Dunshee Wayne K	Antiviral compositions and methods of use
EP3733161A1 (de)	2007-10-12	2020-11-04	Novartis AG	Zusammensetzung mit sphingosin-1-phosphat (s1p)-rezeptormodulatoren
RU2361604C1 (ru) *	2007-10-29	2009-07-20	Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий)	Способ лечения атопического дерматита
PL2278960T5 (pl)	2008-03-17	2020-06-29	Actelion Pharmaceuticals Ltd.	Schemat dawkowania dla selektywnego agonisty receptora sip1
US8461362B2 (en) *	2009-04-13	2013-06-11	The Ohio State University Research Foundation	Protein phosphatase 2A-activating agents
WO2010121111A1 (en) *	2009-04-17	2010-10-21	The Ohio State University Research Foundation	Antiadhesion agents
WO2011009634A2 (en) *	2009-07-24	2011-01-27	Ratiopharm Gmbh	Process for producing fingolimod salts
CN101966145A (zh) *	2010-09-21	2011-02-09	浙江大学	2-氨基-2-(2-[4-辛基苯基]乙基)-1,3-丙二醇盐酸盐制剂及其制备方法
WO2012071524A1 (en)	2010-11-24	2012-05-31	Ratiopharm Gmbh	Arylsulfonate salts of fingolimod and processes for preparation thereof
US8309768B2 (en)	2010-11-29	2012-11-13	The Ohio State University Research Foundation	FTY720-derived anticancer agents
JP6111202B2 (ja)	2011-01-07	2017-04-05	ノバルティスアーゲー	免疫抑制製剤
AR085749A1 (es)	2011-04-01	2013-10-23	Novartis Ag	Formulaciones
RU2496486C1 (ru)	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
AU2014209141B2 (en)	2013-01-24	2018-05-10	Palvella Therapeutics, Inc.	Compositions for transdermal delivery of mTOR inhibitors
CN105611917A (zh)	2013-10-11	2016-05-25	帝国制药美国公司	局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法
US10675254B2 (en)	2013-10-11	2020-06-09	Teikoku Seiyaku Co., Ltd.	Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
WO2016135644A1 (en)	2015-02-26	2016-09-01	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3565520B1 (de)	2017-01-06	2026-02-25	Palvella Therapeutics, Inc.	Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
US10798783B2 (en) *	2017-02-15	2020-10-06	Continuous Composites Inc.	Additively manufactured composite heater
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
CN115300508A (zh) *	2017-07-05	2022-11-08	艾缇亚(上海)制药有限公司	包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
US11000513B2 (en)	2018-07-02	2021-05-11	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU374086A1 (ru) *	1971-06-11	1973-03-20		ЛЕКАРСТВЕННОЕ СРЕДСТВО''^ --''ОсНАЯ'•'^^^bju;r---jc^'-;^..':. :0 •--.:А \|:'*''~'"~~ •' - ——«-.«aSJ^iH.
SE7510988L (sv) *	1975-10-01	1977-04-02	Draco Ab	Nya farmaceutiskt aktiva foreningar
US4861800A (en) *	1987-08-18	1989-08-29	Buyske Donald A	Method for administering the drug deprenyl so as to minimize the danger of side effects
EP0356399A3 (de) *	1988-08-26	1991-03-20	Sandoz Ag	Substituierte 4-Azatricyclo (22.3.1.04.9) octacos-18-en-Derivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen
EP0501579A1 (de) *	1991-02-28	1992-09-02	Merck Frosst Canada Inc.	Naphthalinlactone als Inhibitoren der Leukotrien-Biosynthese
IL102236A0 (en) *	1991-06-27	1993-01-14	Ltt Inst Co Ltd	Topical preparations containing cyclosporin
IT1252865B (it) *	1991-12-31	1995-06-28	Lifegroup Spa	N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
IT1252866B (it) *	1991-12-31	1995-06-28	Lifegroup Spa	N-acilderivati di aminoalcooli con acidi policarbossilici atti alla modulazione dei mastociti nei processi infiammatori su base neuroimmunogenica
DE69321823T2 (de) *	1992-10-21	1999-06-02	Taito Co., Ltd., Tokio/Tokyo	2-amino-1, 3- propandiolverbindung und immunosuppressium
JPH06256182A (ja) *	1993-03-05	1994-09-13	L T T Kenkyusho:Kk	外用製剤
JPH07188046A (ja) *	1993-12-27	1995-07-25	L T T Kenkyusho:Kk	シクロスポリン含有外用治療薬及びその製造方法
WO1995022343A1 (en) *	1994-02-17	1995-08-24	Shiseido Company, Ltd.	Cyclosporin-containing emulsion composition
JPH1180026A (ja) *	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法

1996
- 1996-12-24 WO PCT/JP1996/003757 patent/WO1997024112A1/ja not_active Ceased
- 1996-12-24 DE DE69633613T patent/DE69633613T2/de not_active Expired - Lifetime
- 1996-12-24 ES ES96942623T patent/ES2230571T3/es not_active Expired - Lifetime
- 1996-12-24 CZ CZ972704A patent/CZ285953B6/cs not_active IP Right Cessation
- 1996-12-24 NZ NZ324453A patent/NZ324453A/xx not_active IP Right Cessation
- 1996-12-24 PT PT96942623T patent/PT812588E/pt unknown
- 1996-12-24 CA CA002213989A patent/CA2213989C/en not_active Expired - Lifetime
- 1996-12-24 US US08/894,728 patent/US6121329A/en not_active Expired - Lifetime
- 1996-12-24 RU RU97115893/14A patent/RU2156127C2/ru active
- 1996-12-24 IL IL12162596A patent/IL121625A/en not_active IP Right Cessation
- 1996-12-24 HU HU9800034A patent/HU224814B1/hu unknown
- 1996-12-24 EP EP96942623A patent/EP0812588B1/de not_active Expired - Lifetime
- 1996-12-24 AT AT96942623T patent/ATE279185T1/de active
- 1996-12-24 SK SK1157-97A patent/SK282225B6/sk not_active IP Right Cessation
- 1996-12-24 SI SI9630694T patent/SI0812588T1/xx unknown
- 1996-12-24 AU AU11729/97A patent/AU705320B2/en not_active Expired
2000
- 2000-06-12 US US09/592,550 patent/US6197829B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
RU2156127C2 (ru)	2000-09-20
ATE279185T1 (de)	2004-10-15
IL121625A0 (en)	1998-02-08
EP0812588B1 (de)	2004-10-13
WO1997024112A1 (en)	1997-07-10
DE69633613D1 (de)	2004-11-18
CA2213989A1 (en)	1997-07-10
HUP9800034A3 (en)	1999-12-28
EP0812588A1 (de)	1997-12-17
DE69633613T2 (de)	2006-02-09
PT812588E (pt)	2005-01-31
CZ270497A3 (cs)	1998-01-14
SK282225B6 (sk)	2001-12-03
AU705320B2 (en)	1999-05-20
HUP9800034A2 (hu)	1999-05-28
NZ324453A (en)	2000-03-27
US6121329A (en)	2000-09-19
ES2230571T3 (es)	2005-05-01
SI0812588T1 (en)	2005-02-28
EP0812588A4 (de)	2002-11-06
IL121625A (en)	2001-09-13
CZ285953B6 (cs)	1999-12-15
US6197829B1 (en)	2001-03-06
AU1172997A (en)	1997-07-28
CA2213989C (en)	2007-05-29
SK115797A3 (en)	1998-02-04

Publication	Publication Date	Title
HU224814B1 (en)	2006-02-28	Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US6476004B1 (en)	2002-11-05	Pharmaceutical composition
EP0990440B1 (de)	2008-10-29	Arzneimittel zubereitung enthaltend 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, ein lecithin und ein saccharid
EP1050301B1 (de)	2009-03-25	Medizinische Zusammensetzungen enthaltend 2-Amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol
JPWO1998037875A1 (ja)	2000-07-25	医薬組成物
JPWO1999036065A1 (ja)	2002-09-24	医薬組成物
HU206833B (en)	1993-01-28	Process for producing pharmaceutical compositions containing calcitoninogen-like peptide-amide or pharmaceutically acceptable salt thereof for treating erective disfunctions
KR970008156B1 (ko)	1997-05-21	소아의 비정형 폐렴의 치료 및 예방에 유용한 펜타미딘 염
JP2002534389A (ja)	2002-10-15	女性性機能障害の治療のための方法および組成物
EP1647274A1 (de)	2006-04-19	Mittel zur behandlung von pruritus mit einem piperidin-derivat als wirkstoff
JP2002241272A (ja)	2002-08-28	医薬処方組成物
JPWO1997024112A1 (ja)	1998-03-31	外用剤
AU2002324026B2 (en)	2005-07-14	Pharmaceutical compositions
HK1036006A (en)	2001-12-21	Medicinal compositions
WO1993012783A1 (fr)	1993-07-08	Pommade oleagineuse
JPH11501916A (ja)	1999-02-16	あるシスチン誘導体の薬理学的使用
HK1027039B (en)	2009-11-27	Pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharide
HK1027959B (en)	2005-07-29	Drug composition
JPWO1993012783A1 (ja)	1994-01-06	油脂性軟膏